Oramed Pharmaceuticals (NASDAQ:ORMP) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.09), Fidelity Earnings reports. Oramed Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 28.75%.
ORMP traded down $0.12 during trading on Friday, hitting $4.34. The company’s stock had a trading volume of 8,185 shares, compared to its average volume of 164,833. Oramed Pharmaceuticals has a twelve month low of $2.40 and a twelve month high of $5.71. The business’s fifty day simple moving average is $4.28 and its 200 day simple moving average is $3.45. The firm has a market capitalization of $102.75 million, a price-to-earnings ratio of -13.51 and a beta of 1.58.
Separately, Alliance Global Partners began coverage on Oramed Pharmaceuticals in a research report on Thursday, December 3rd. They set a “buy” rating and a $11.00 price target for the company.
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
See Also: How does quantitative easing work?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.